Nusinersen API

Nusinersen is an oligonucleotide drug approved by the FDA in 2016 for the treatment of spinal muscular atrophy (SMA). SMA is a rare genetic disease that affects the muscles used for movement, breathing, and swallowing. Nusinersen is the first and Continue reading Nusinersen API

High Potency Active Pharmaceutical Ingredients for Generic Drugs

Featured

Rare diseases affect a small percentage of the population and often have limited treatment options. However, the availability of High Potency Active Pharmaceutical Ingredients (HPAPIs) for generic drugs has played a critical role in addressing these diseases. HPAPIs are highly Continue reading High Potency Active Pharmaceutical Ingredients for Generic Drugs